Abstract:Background: Coronavirus Disease 2019 (Covid-19) continues to challenge the limits of our knowledge and our healthcare system. Here we sought to define the host immune response, a.k.a, the "cytokine storm" that has been implicated in fatal COVID-19 using an AI-based approach. Method: Over 45,000 transcriptomic datasets of viral pandemics were analyzed to extract a 166-gene signature using ACE2 as a 'seed' gene; ACE2 was rationalized because it encodes the receptor that facilitates the entry of SARS-CoV-2 (the virus that causes COVID-19) into host cells. An AI-based approach was used to explore the utility of the signature in navigating the uncharted territory of Covid-19, setting therapeutic goals, and finding therapeutic solutions. Findings: The 166-gene signature was surprisingly conserved across all viral pandemics, including COVID-19, and a subset of 20-genes classified disease severity, inspiring the nomenclatures ViP and severe-ViP signatures, respectively. The ViP signatures pinpointed a paradoxical phenomenon wherein lung epithelial and myeloid cells mount an IL15 cytokine storm, and epithelial and NK cell senescence and apoptosis determine severity/fatality. Precise therapeutic goals could be formulated; these goals were met in high-dose SARS-CoV-2-challenged hamsters using either neutralizing antibodies that abrogate SARS-CoV-2•ACE2 engagement or a directly acting antiviral agent, EIDD-2801. IL15/IL15RA were elevated in the lungs of patients with fatal disease, and plasma levels of the cytokine prognosticated disease severity. Interpretation: The ViP signatures provide a quantitative and qualitative framework for titrating the immune response in viral pandemics and may serve as a powerful unbiased tool to rapidly assess disease severity and vet candidate drugs. Funding: This work was supported by the National Institutes for Health (NIH) [grants CA151673 and GM138385 (to DS) and AI141630 (to P.G), DK107585-05S1 (SD) and AI155696 (to P.G, D.S and S.D), U19-AI142742 (to S. C, cchi: Cooperative Centers for Human Immunology)]; Research Grants Program Office (RGPO) from the University of California Office of the President (UCOP) (R00RG2628 & R00RG2642 to P.G, D.S and S.D); the UC San Diego Sanford Stem Cell Clinical Center (to P.G, D.S and S.D); LJI Institutional Funds (to S.C); the VA San Diego Healthcare System Institutional funds (to L.C.A). GDK was supported through The American Association of Immunologists Intersect Fellowship Program for Computational Scientists and Immunologists. One sentence summary: The host immune response in COVID-19.

AI-guided discovery of the invariant host response to viral pandemics

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis

A T-Cell-Derived 3-Gene Signature Distinguishes SARS-CoV-2 from Common Respiratory Viruses

Discovery and Functional Interrogation of the Virus and Host RNA Interactome of SARS-Cov-2 Proteins

Transcriptomics Curation of SARS-CoV-2 Related Host Genes in Mice With COVID-19 Comorbidity: A Pilot Study

Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses

Deep dissection of the antiviral immune profile of patients with COVID-19

Proteomics Reveals Antiviral Host Response and NETosis During Acute COVID-19 in High-Risk Patients

Proteomic Signature of Host Response to SARS-CoV-2 Infection in the Nasopharynx

Human SARS-CoV-2 challenge uncovers local and systemic response dynamics

Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients

Biomarkers and Immune Repertoire Metrics Identified by Peripheral Blood Transcriptomic Sequencing Reveal the Pathogenesis of COVID-19

The transcriptomic profiling of SARS-CoV-2 compared to SARS, MERS, EBOV, and H1N1

Integrated multi-omics analyses identify anti-viral host factors and pathways controlling SARS-CoV-2 infection

Analysis of Infected Host Gene Expression Reveals Repurposed Drug Candidates and Time-Dependent Host Response Dynamics for COVID-19.

Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions

SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets

Integrated Interactome and Transcriptome Analysis Reveals Key Host Factors Critical for SARS-CoV-2 Infection.

Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epithelia